A phase III ALUR study showed that patients with ALK-positive NSCLC BMs treated with alectinib had a significantly higher ORR than patients who underwent chemotherapy (54.2% vs. 0, p < 0.001) [87]. This evidence concerns the gene ALK and non-small cell lung carcinoma.